Education
About Us
Working with TipRanks
Follow Us
Chimeric Therapeutics Ltd. (AU:CHM)
ASX:CHM
CHM Stock Chart & Stats
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume2.58M
Average Volume (3M)2.05M
Market Cap
AU$11.37M
Enterprise ValueAU$1.97M
Total Cash (Recent Filing)AU$5.07M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Aug 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,249,123,500
10 Day Avg. Volume3,014,500
30 Day Avg. Volume2,054,362
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Chimeric Therapeutics Ltd. News
CHM FAQ
What was Chimeric Therapeutics Ltd.’s price range in the past 12 months?
Chimeric Therapeutics Ltd. lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Chimeric Therapeutics Ltd.’s market cap?
Chimeric Therapeutics Ltd.’s market cap is AU$11.37M.
When is Chimeric Therapeutics Ltd.’s upcoming earnings report date?
Chimeric Therapeutics Ltd.’s upcoming earnings report date is Aug 28, 2025 which is in 23 days.
How were Chimeric Therapeutics Ltd.’s earnings last quarter?
Currently, no data Available
Is Chimeric Therapeutics Ltd. overvalued?
According to Wall Street analysts Chimeric Therapeutics Ltd.’s price is currently Overvalued.
Does Chimeric Therapeutics Ltd. pay dividends?
Chimeric Therapeutics Ltd. does not currently pay dividends.
What is Chimeric Therapeutics Ltd.’s EPS estimate?
Chimeric Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chimeric Therapeutics Ltd. have?
Chimeric Therapeutics Ltd. has 3,249,123,500 shares outstanding.
What happened to Chimeric Therapeutics Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Chimeric Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:CHM
Chimeric Therapeutics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CHM Sentiment 81%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-180.09%
Trailing 12-Months
Asset Growth
-30.02%
Trailing 12-Months
Company Description
Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. (CHM) is a biotechnology company focused on the development of novel cell therapies for cancer treatment. The company leverages its expertise in chimeric antigen receptor T-cell (CAR-T) technology to design and develop next-generation therapies aimed at improving patient outcomes. Chimeric Therapeutics is committed to pioneering advanced approaches in immunotherapy, with a pipeline of products targeting various cancer indications.
Chimeric Therapeutics Ltd. (CHM) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Ownership Overview
6.71% Insiders
―
Mutual Funds
― Other Institutional Investors
93.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---